The positive predictive value of ct-proAVP (copeptin) in patients with STEMI

Recently Reinstadler et al reported on a study in n=54 patients diagnosed with STEMI who underwent copeptin sampling 2 (1–3) days after the index event and Cardiac Magnetic Resonance (CMR) on the same day. A follow-up CMR study was done after 4 months in n=47 patients. The authors found a strong and significant correlation between day 2 copeptin and ejection fraction, end systolic volume, stroke volume and per cent infarct mass. Additionally, using optimised cutoffs, adverse remodelling could be excluded by the combination of copeptin with NT-proBNP.1 Copeptin is a stable glycopeptide comprising the C-terminal part of the AVP arginine-vasopressine prohormone.2 Copeptin is known to be released by the hypophysis early upon the trigger of arterial underfilling, for example, in the case of immediate drop of blood pressure, cardiac output or both, like in acute myocardial infarction (AMI). It has been reported by many...
Source: Heart - Category: Cardiology Authors: Tags: Drugs: cardiovascular system, Hypertension, Interventional cardiology, Acute coronary syndromes, Clinical diagnostic tests Editorials Source Type: research